Bibliography
- Giles T, Aranda J, Suh D, et al. Ethnic/racial variations in blood pressure awareness, treatment, and control. J Clin Hypertens 2007;9:345-54
- Chobanian A, Bakris G, Black H. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560-72
- Hajjar I, Kotchen T. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206
- Holland N, Segraves D, Nnadi V, et al. Identifying barriers to hypertension care: implications for quality improvement initiatives. Dis Manage 2008;11(2):71-7
- Krum H, Gilbert R. Novel therapies blocking the renin–angiotensin–aldosterone system in the management of hypertension and related disorders. J Hypertens 2007;25:25-35
- Ferrario C. Role of angiotensin II in cardiovascular disease-therapeutic implications of more than a century of research. JRAAS 2006;7:3-14
- Schmeider R, Hilgers K, Schlaich M, et al. Renin–angiotensin system and cardiovascular risk. Lancet 2007;369:1208-19
- Jegerlehner A, Tissot A, Lechner F, et al. A molecular assembly system that renders antigens of choice highly receptive for induction of protective B cell responses. Vaccine 2002;20:3104-12
- Spohn G, Bachmann M. Therapeutic vaccination to block receptor-ligand interactions. Expert Opin Biol Ther 2003;3(3):469-76
- Lechner F, Jegerlehner A, Tissot A, et al. Virus-like particles as a modular system for novel vaccines. Intervirology 2002;45:212-7
- Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity. Eur J Immunol 2005;35:2031-40
- Kundig TM, Senti G, Schnetzler G, et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006;117:1470-6
- Ambuhl P, Tissot A, Fulurija A, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007;25:63-72
- Tissot A, Maurer P, Nussberger J, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008;371:821-7
- Michel JB, Galen FX, Guettier C, et al. Immunological approach to blockade of the renin–substrate reaction. J Hypertens 1989;7(Suppl 2):S63-70
- Michel JB. Renin–angiotensin vaccine: old story, new project ‘efficacy versus safety’. Clin Sci 2004;107:145-7
- Menard J. A vaccine for hypertension. J Hypertens 2007;25:41-6
- Ambuhl PM, TIssot AC, Fulurija A, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and Phase I safety and immunogenicity. J Hypertens 2007;25:63-72